Business Context and Reporting Period
This Form 8-K is a current report filed by OncoGenex Pharmaceuticals, Inc. (noted as Achieve Life Sciences, Inc. in metadata) on May 26, 2016. The filing reports on corporate governance events occurring on the same date, specifically the granting of stock options to directors and the results of the 2016 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity compensation matters rather than financial performance.
Material Changes and Corporate Actions
Director Stock Options (Item 5.02)
- Jack Goldstein (Chairman): Granted an option to purchase up to 31,500 shares of common stock.
- Non-Employee Directors (Neil Clendeninn, Martin Mattingly, Stewart Parker, David Smith): Each granted an option to purchase up to 22,500 shares of common stock.
- Terms: Exercise price of $1.00 per share. Options vest on the earlier of May 26, 2017, or the date immediately prior to the next annual meeting, contingent on continued service.
2016 Annual Meeting Results (Item 5.07)
- Director Elections: Six directors were elected to serve until the next annual meeting. All received significant "For" votes (ranging from approximately 5.76 million to 5.82 million) with "Withheld" votes ranging from approximately 512,000 to 574,000. Broker non-votes totaled 14,829,365 for all director candidates.
- Auditor Ratification: Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016.
- Voting Tally for Auditor: 20,991,483 For, 90,299 Against, 84,344 Abstain, 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the specific events of the annual meeting and the director compensation grant.
Investor Verification Checklist
- Verify the total number of outstanding shares to assess the dilution impact of the 142,500 new options granted to directors.
- Confirm the current market price of the stock relative to the $1.00 exercise price to evaluate the intrinsic value of the grants.
- Review the proxy statement for the 2016 Annual Meeting for detailed biographies of the elected directors and the rationale for the auditor ratification.
- Check subsequent filings for the actual vesting dates and any changes in director tenure.